Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).

2.50
Hdl Handle:
http://hdl.handle.net/10541/71935
Title:
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).
Authors:
Moorman, Anthony V; Richards, Susan M; Robinson, Hazel M; Strefford, Jon C; Gibson, Brenda E; Kinsey, Sally E; Eden, Tim O B; Vora, Ajay J; Mitchell, Christopher D; Harrison, Christine J
Abstract:
Patients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.
Affiliation:
Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, United Kingdom. avm@soton.ac.uk
Citation:
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). 2007, 109 (6):2327-30 Blood
Journal:
Blood
Issue Date:
15-Mar-2007
URI:
http://hdl.handle.net/10541/71935
DOI:
10.1182/blood-2006-08-040436
PubMed ID:
17095619
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMoorman, Anthony V-
dc.contributor.authorRichards, Susan M-
dc.contributor.authorRobinson, Hazel M-
dc.contributor.authorStrefford, Jon C-
dc.contributor.authorGibson, Brenda E-
dc.contributor.authorKinsey, Sally E-
dc.contributor.authorEden, Tim O B-
dc.contributor.authorVora, Ajay J-
dc.contributor.authorMitchell, Christopher D-
dc.contributor.authorHarrison, Christine J-
dc.date.accessioned2009-06-30T11:54:28Z-
dc.date.available2009-06-30T11:54:28Z-
dc.date.issued2007-03-15-
dc.identifier.citationPrognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). 2007, 109 (6):2327-30 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid17095619-
dc.identifier.doi10.1182/blood-2006-08-040436-
dc.identifier.urihttp://hdl.handle.net/10541/71935-
dc.description.abstractPatients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.en
dc.language.isoenen
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshChromosomes, Human, Pair 21-
dc.subject.meshCytogenetics-
dc.subject.meshFemale-
dc.subject.meshGene Amplification-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshMale-
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma-
dc.subject.meshPrognosis-
dc.subject.meshSurvival Rate-
dc.titlePrognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).en
dc.typeArticleen
dc.contributor.departmentLeukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, United Kingdom. avm@soton.ac.uken
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.